Evogene (EVGN) Competitors $1.16 -0.04 (-3.33%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.16 0.00 (-0.09%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, TOMZ, ENFY, SNES, GURE, NITO, CNEY, BSLK, HGAS, and TANHShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Senestech (SNES), Gulf Resources (GURE), N2OFF (NITO), CN Energy Group. (CNEY), Bolt Projects (BSLK), Global Gas (HGAS), and Tantech (TANH). Evogene vs. Its Competitors Carisma Therapeutics TOMI Environmental Solutions Enlightify Senestech Gulf Resources N2OFF CN Energy Group. Bolt Projects Global Gas Tantech Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership. Do analysts rate CARM or EVGN? Carisma Therapeutics currently has a consensus target price of $1.93, indicating a potential upside of 517.98%. Evogene has a consensus target price of $3.50, indicating a potential upside of 201.72%. Given Carisma Therapeutics' higher probable upside, equities analysts clearly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CARM or EVGN? Carisma Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.59, indicating that its stock price is 59% more volatile than the S&P 500. Is CARM or EVGN more profitable? Evogene has a net margin of -224.82% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -137.38% Evogene -224.82%-102.40%-39.19% Do institutionals and insiders believe in CARM or EVGN? 44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 10.4% of Evogene shares are owned by institutional investors. 6.9% of Carisma Therapeutics shares are owned by insiders. Comparatively, 7.4% of Evogene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the media favor CARM or EVGN? In the previous week, Carisma Therapeutics and Carisma Therapeutics both had 1 articles in the media. Carisma Therapeutics' average media sentiment score of 0.00 equaled Evogene'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Carisma Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evogene 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better earnings and valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.66-$60.48M-$1.56-0.20Evogene$8.51M0.73-$16.49M-$2.69-0.43 SummaryCarisma Therapeutics beats Evogene on 8 of the 15 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.22M$3.01B$5.52B$9.37BDividend YieldN/A2.44%4.74%4.12%P/E Ratio-0.4317.7428.9323.80Price / Sales0.73309.13440.5196.33Price / CashN/A41.6335.0756.59Price / Book0.428.488.255.54Net Income-$16.49M-$55.06M$3.25B$259.97M7 Day Performance-11.45%-3.99%-3.75%-4.67%1 Month Performance-14.71%8.53%2.99%3.29%1 Year Performance-76.03%6.51%25.34%17.92% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.0745 of 5 stars$1.16-3.3%$3.50+201.7%-76.0%$6.22M$8.51M-0.43140CARMCarisma Therapeutics2.1933 of 5 stars$0.37-5.9%$1.93+427.0%-68.1%$16.21M$19.63M-0.2320Positive NewsUpcoming EarningsGap DownTOMZTOMI Environmental Solutions2.9366 of 5 stars$0.96-2.0%$3.50+264.4%+45.5%$19.62M$8.20M-5.6520News CoverageUpcoming EarningsENFYEnlightifyN/A$0.95-3.9%N/AN/A$15.57M$95.85M-0.76424Gap DownSNESSenestech2.114 of 5 stars$5.47-3.0%$10.00+82.8%+21.5%$12.69M$1.86M-0.7230News CoveragePositive NewsUpcoming EarningsGUREGulf Resources0.4881 of 5 stars$0.67+1.3%N/A-38.4%$8.80M$7.66M-0.12420News CoveragePositive NewsNITON2OFF0.9547 of 5 stars$0.27-13.6%N/A-46.6%$8.16M$232K0.002News CoveragePositive NewsShort Interest ↑CNEYCN Energy Group.1.104 of 5 stars$2.55-1.5%N/A-72.8%$7.80M$50.96M0.00160News CoveragePositive NewsBSLKBolt ProjectsN/A$2.69+5.5%N/AN/A$5.26M$1.53M0.0012Positive NewsHGASGlobal GasN/A$0.19+58.3%N/A-35.8%$1.54MN/A0.002Gap UpHigh Trading VolumeTANHTantech1.1028 of 5 stars$2.13+4.4%N/A-76.8%$190K$42.94M0.0070News CoveragePositive News Related Companies and Tools Related Companies CARM Competitors TOMZ Competitors ENFY Competitors SNES Competitors GURE Competitors NITO Competitors CNEY Competitors BSLK Competitors HGAS Competitors TANH Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 8/3/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredInvestigating the Most Controversial Stock on EarthTesla’s wild price swings may not be random after all. Hedge fund veteran Larry Benedict has uncovered a st...Brownstone Research | SponsoredThis New Rule Could Change EverythingA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big ...American Alternative | SponsoredSell these "safe" blue chips immediatelyInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EVGN Stock Alerts